KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Cash: 2009-2025

Historic Change in Cash for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to -$34.2 million.

  • Vertex Pharmaceuticals' Change in Cash fell 105.20% to -$34.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$300.3 million, marking a year-over-year increase of 94.88%. This contributed to the annual value of -$5.8 billion for FY2024, which is 4051.83% down from last year.
  • Vertex Pharmaceuticals' Change in Cash amounted to -$34.2 million in Q3 2025, which was down 111.53% from $296.6 million recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Change in Cash ranged from a high of $1.3 billion in Q4 2022 and a low of -$4.6 billion during Q2 2024.
  • In the last 3 years, Vertex Pharmaceuticals' Change in Cash had a median value of -$34.2 million in 2025 and averaged -$505.8 million.
  • Its Change in Cash has fluctuated over the past 5 years, first soared by 554.96% in 2022, then plummeted by 633.74% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' Change in Cash (Quarterly) stood at $519.9 million in 2021, then surged by 156.78% to $1.3 billion in 2022, then tumbled by 155.75% to -$744.3 million in 2023, then increased by 9.19% to -$675.9 million in 2024, then plummeted by 105.20% to -$34.2 million in 2025.
  • Its Change in Cash was -$34.2 million in Q3 2025, compared to $296.6 million in Q2 2025 and $113.2 million in Q1 2025.